To successfully conduct U.S. ensayo clínicos for RCI001, we have completó a business acuerdo with Ora, a clinical investigación organization specializing in eye diseases, and are entering full-scale clinical operations.
With the producción of ensayo clínico raw materials now complete, we are making preparations in close colaboración with Ora to successfully complete the U.S. Phase 2 ensayo clínico in 2022.
Ora, Inc., a U.S.-based CRO and SMO specializing in enfermedad oftálmicas, realizará the ensayo clínico using its proprietary CAE™ (Controlled Adverse Environment) model — a more efficient and rapid approach based on extensive experience conducting enfermedad de ojo seco ensayo clínicos.
To successfully complete the U.S. ensayo clínico, we have recruited Clinical Team Leader Yuseung Ha, who has years of clinical investigación experience at IQVIA, and restructured the clinical team as an independent department to build a more agile clinical response environment.